Market News / Story
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Pric…
BusinessWire ·
BusinessWire reports: bioAffinity Technologies, Inc. (, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.…
Related stories
Trump bought up to $25 million in Meta and millions in SpaceX debt in AugustRead story summary
President Donald Trump disclosed more than 500 securities transactions in August, including a purchase of up to $25 million in Meta stock and an investment of as much as $5 million in SpaceX debt two days before he signed a sweeping policy aimed at expanding U.S. commercial space transportation, according to a newly released financial disclosure. The 517 ...
VIEW SOURCE